Muscle Deterioration in Hospitalized Cancer Patients
Official title: Assessment of Muscle Deterioration in Hospitalized Cancer Patients Using Surface Electromyography, Dynamometry, and Bioimpedance
Run by University of Salamanca · NCT07387770 · Data updated 2026-11-12
A study test to see how muscle loss progresses in adults with cancer who are in the hospital and to help identify who might need muscle-support therapies.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University of Salamanca Academic / other |
| Locations | 1 site (Salamanca, Salamanca) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | November 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT07387770 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with confirmed cancer, hospitalized for at least four days, able to give consent and complete questionnaires, and able to perform contractions of arms and legs.
✕Probably not a fit
Patients with severe cognitive impairment, extensive skin lesions, implanted electronic devices (relative contraindication for bioimpedance), or other contraindications to strength testing may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This protocol describes a longitudinal evaluation of skeletal muscle deterioration in hospitalized cancer patients using a multimodal approach. It combines questionnaires, functional tests, body composition analysis, neuromuscular measurements, and serum biomarkers to monitor changes over time. Daily functional measurements will be recorded in 45–50 eligible patients with confirmed malignancy hospitalized for at least four days, to identify early signs of cachexia and sarcopenia and inform potential interventions.
Why it matters
Potential benefit: If successful, the study could improve early detection of muscle deterioration and guide timely supportive treatments for cancer patients in hospital.
How similar studies have gone: Previous research supports using multimodal assessments to detect muscle deterioration in cancer; this protocol builds on established measures but applies them longitudinally in acutely hospitalized patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: more than 18 years * Confirmed malignant neoplasm diagnosis * Hospitalization anticipated for at least 4 days * Capacity to provide informed consent and complete questionnaires * ECOG performance status 0-3 * Ability to perform voluntary contractions of upper and lower extremities Exclusion Criteria: * Medical contraindications to strength testing (recent fractures, acute injuries) - Severe neurological impairment precluding functional assessment * Implanted electronic devices (relative contraindication for bioimpedance) * Severe cognitive impairment preventing questionnaire completion * Extensive skin lesions preventing electrode placement for sEMG
Where it's running
-
Hospital Universitario de Salamanca
Salamanca, Salamanca, Spain Recruiting
Study contacts
- Study coordinator: Inés Dr. Llamas-Ramos
- Email: inesllamas@usal.es
- Phone: +34630720990
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NUT Project: Nutritional Support in Thoracic Cancer
We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.
-
My Care My Voice: helping patients and clinicians start palliative care conversations
This program tries to help oncologists, hospital staff, and adults with advanced cancer start timely palliative care conversations using brief materials and simple workflow changes in three Belgian hospitals.
-
Metamizole (Optalgin) impact on anti‑Xa levels in cancer patients on apixaban or rivaroxaban
This study will test whether taking metamizole (Optalgin) changes anti‑Xa blood levels in adults with cancer who are taking apixaban or rivaroxaban.
-
Financial burden for radiotherapy patients in Italy
This project will use a short Italian questionnaire to see if people getting radiotherapy in Italy face financial problems before, during, and after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.